| Name | Title | Contact Details |
|---|---|---|
Devin Smith |
General Counsel and Chief Compliance Officer | Profile |
Founded in 2014, Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway.
We are a groundbreaking science-based company creating scalable, safer insect control technology that will improve the quality of life for all humans and our world.
Pointilliste is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
VBI Vaccines Inc.is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5 Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch`s development stage product candidates include AC5-G, AC5-V and AC5 Surgical Hemostat, among others.1,2